Epitalon Label Updates 2020 to 2026: FDA Status, Safety Data, and Regulatory Timeline

Print or save as PDFOpens the printable question sheet and your print dialog. No sign-up.

Is there an epitalon label to update?

No. A US label is the prescribing information attached to an approved drug application, and epitalon has no approved application. FDA's July 2026 review found no approved epitalon product in the United States and no product authorized by the European Medicines Agency or approved in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy [1]. What is sold online instead is research-use-only vials of 10 mg to 50 mg, capsules and oral sprays [1].

FDA did grant epitalon an orphan drug designation for retinitis pigmentosa on September 2, 2010, and withdrew that designation on January 6, 2016 [1]. An orphan designation is not an approval and brought no label with it.

A 2015 analysis also identified epitalon in two illegal pharmaceutical preparations marketed for cancer, old age and retinitis pigmentosa [1][5].

Timeline of epitalon regulatory events, 2020 to 2026

2018 to 2020. A Kentucky pharmacy compounded and distributed epitalon products between October 25, 2018 and April 1, 2020, according to the US Attorney's office. FDA found no pharmacy that compounds epitalon and no outsourcing facility reporting it [1].

April 22, 2026. FDA's page on bulk substances that may present significant safety risks lists epitalon in the 'nominated but withdrawn' table, which holds substances previously in category 2 whose nominators withdrew them. FDA's stated concern is that it 'has not identified safety-related information regarding epitalon for the proposed route of administration,' so it lacks enough information to know whether the drug would cause harm, and injectable peptides may pose immunogenicity risk from aggregation and impurities. Removal from category 2 was not a finding that epitalon is safe [6].

May 14, 2026 and March 21, 2025. Epitalon appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026), and is absent from the outsourcing-facility list (updated March 21, 2025). The category 1 policy, under which FDA generally does not act against compounders who meet the conditions, does not cover it [7][8][9].

July 2026. In a briefing document for the Pharmacy Compounding Advisory Committee, FDA staff proposed that neither epitalon free base nor epitalon acetate be added to the FDA pharmacy bulk-substance list. FDA evaluated only the nominated use for insomnia; the other nominated uses, such as anti-aging and telomere lengthening, were not evaluated for lack of information. Staff's reasons: epitalon is not well characterized, has limited historical use, has no evidence of effectiveness for insomnia, and many FDA-approved insomnia drugs already exist. The nominated products were 10 mg/mL and 3000 microgram/mL subcutaneous injections [1].

July 24, 2026. The committee reviewed epitalon and voted in favor of adding it to the list, against staff's recommendation. The vote is advice only and not binding; epitalon is not on the list, and adding it requires formal rulemaking [2][3].

October 28, 2026. HHS filed a draft enforcement-discretion policy for compounding with certain peptides (Federal Register document 2026-22192, publication scheduled October 30, 2026, comments due two weeks after publication) naming epitalon among six peptides. It covers epitalon acetate given subcutaneously or intramuscularly in intermittent courses, and says HHS 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with it if the policy's conditions are met, such as a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and a label reading 'This is a compounded drug product. Not for resale.' [3][4]. The notice states that the policy does not establish any rights for any person, is not binding on HHS or the public, and may be revisited if a safety signal or product quality issue arises [3].

What safety data exists as of 2026?

With no approval there is no label warning section and no label adverse-reaction table. FDA found no clinical study that assessed epitalon's safety. Its search of the adverse-event database (FAERS) through December 8, 2025 and of the food and supplement complaint system through December 5, 2025 retrieved no epitalon reports. One small study provided no safety data, and one Russian-language report stated only 'no side effects' without giving a dose, route or number of people. FDA concluded there are no clinical data supporting its safety and raised an immunogenicity concern for subcutaneous injection [1]. FDA found no pharmacokinetic data for epitalon [1].

The mechanistic concern FDA named is cancer risk: epitalon activates telomerase and lengthens telomeres in cultured cells, longer telomeres are generally linked to higher cancer risk, and FDA warned that epitalon therefore has a mechanistic potential to be carcinogenic. The mouse studies of cancer and chromosome damage were too limited, using one fixed dose in female mice only with short exposure, to show safety [1][10].

What the human studies actually measured

FDA found three human studies of epitalon, none of them in insomnia [1].

• Two sublingual studies in night-shift workers. In the one described in detail, 75 healthy women aged 40 to 50 were enrolled, mostly night-shift workers; 40 had low melatonin output and were split into two groups of 20. A sublingual spray delivering about 0.5 mg per day or placebo was used for 20 days. Urinary 6-sulfatoxymelatonin rose about 1.7-fold on epitalon and did not change on placebo. 83% versus 25% were described as improved in mood and physical condition, but no sleep outcomes were measured, blinding was not specified, and the study was short and small [1].
• One eye-injection study in retinitis pigmentosa. This older controlled study reports a 'positive clinical effect in 90% of the cases' in patients with degenerative retinal lesions, with no sample sizes, design details or numbers given in the abstract [11]. FDA describes the epitalon as injected beside the eye [1]. It has not been replicated and is not a modern randomized trial.

The telomere finding comes from a laboratory dish, not from people: adding epitalon to telomerase-negative human fetal fibroblast cultures induced the catalytic subunit of telomerase, telomerase activity and telomere elongation [10].

A 2026 narrative review that searched through September 22, 2026 concluded that human evidence is limited to small physiological or biomarker studies plus an older controlled study in retinitis pigmentosa, that no adequately powered randomized trial has established efficacy, that pharmacokinetic, dose-ranging and long-term safety data are inadequate, and that epitalon is 'biologically active but clinically unproven' [12].

Is there a recommended dose?

There is no approved dose. Websites FDA reviewed suggest 5 mg to 10 mg per day by subcutaneous injection or orally, in cycles (one site every 4 months); that is marketing, not evidence. The human studies FDA found used a sublingual spray delivering about 0.5 mg per day for 20 days, and a parabulbar (beside the eye) injection for retinitis pigmentosa [1].

Epitalon is not epithalamin

Epitalon is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, with a molecular weight of about 390 g/mol as the free base and about 450 g/mol as the acetate. It was designed from the amino-acid content of epithalamin, a polypeptide extract of animal pineal gland. FDA treats epitalon and epithalamin as different substances, so studies of epithalamin are not studies of epitalon. FDA says epitalon first appears to have been synthesized in 1999 [1].

What the 2026 activity does not mean

The advisory committee vote and the HHS draft policy are not approvals, and neither adds epitalon to FDA's pharmacy bulk-substance list [1][3]. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed [3].